FierceBiotech ٢٩ يناير ٢٠٢٦ Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials المصدر